Go Pro
NYSE:CNMD

CONMED (CNMD) Stock Price, News & Analysis

CONMED logo
$48.99 -0.78 (-1.56%)
Closing price 08/7/2026 03:59 PM Eastern
Extended Trading
$49.12 +0.13 (+0.26%)
As of 08/7/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About CONMED Stock (NYSE:CNMD)

Advanced

Key Stats

Today's Range
$48.50
$50.30
50-Day Range
$32.02
$51.93
52-Week Range
$31.44
$56.63
Volume
434,404 shs
Average Volume
760,512 shs
Market Capitalization
$1.47 billion
P/E Ratio
26.48
Dividend Yield
N/A
Price Target
$41.40
Consensus Rating
Reduce

Company Overview

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy. The Orthopedics segment offers arthroscopic shavers, burrs and handpieces, as well as joint repair and reconstruction implants. In its Visualization & Energy segment, CONMED provides endoscopic imaging systems, electrosurgical and radiofrequency generators, insufflators, ablation devices and related disposables. These technologies are designed to improve procedural efficiency, safety and patient outcomes.

With a presence in over 70 countries, CONMED sells products through direct sales forces as well as distributor partnerships. The company’s international footprint spans North America, Europe, Latin America, Asia Pacific and select emerging markets. CONMED works closely with healthcare facilities and surgical centers to deliver training, technical support and service solutions tailored to local regulatory requirements and clinical practices.

Leadership at CONMED includes President and Chief Executive Officer Jeffrey M. Dunn, whose tenure has focused on strategic growth through product innovation and targeted acquisitions. Over its history, the company has expanded both organically and via the integration of complementary businesses to broaden its capabilities in key procedural areas. CONMED remains committed to advancing minimally invasive surgical technologies and supporting clinicians worldwide.

AI Generated. May Contain Errors.

CONMED Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

CNMD MarketRank™: 

CONMED scored higher than 55% of companies evaluated by MarketBeat, and ranked 350th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CONMED has received a consensus rating of Reduce. The company's average rating score is 1.63, and is based on no strong buy ratings, no buy ratings, 5 hold ratings, and 3 sell ratings.

  • Downside Risk

    CONMED has a consensus price target of $41.40, representing about 15.5% downside from its current price of $48.99.

  • Amount of Analyst Coverage

    CONMED has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CONMED's stock forecast and price target.
  • Earnings Growth

    Earnings for CONMED are expected to grow by 4.19% in the coming year, from $4.54 to $4.73 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CONMED is 26.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.28.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CONMED is 26.48, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.57.

  • Price to Earnings Growth Ratio

    CONMED has a PEG Ratio of 2.24. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    CONMED has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.76% of the float of CONMED has been sold short.
  • Short Interest Ratio / Days to Cover

    CONMED has a short interest ratio ("days to cover") of 2.47, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CONMED has recently decreased by 8.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CONMED does not currently pay a dividend.

  • Dividend Growth

    CONMED does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, CONMED will have a dividend payout ratio of 12.68% next year. This indicates that CONMED will be able to sustain or increase its dividend.

  • News Sentiment

    CONMED has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for CONMED this week, compared to 3 articles on an average week.
  • Search Interest

    9 people have searched for CNMD on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added CONMED to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CONMED insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.28% of the stock of CONMED is held by insiders.

  • Percentage Held by Institutions

    CONMED has minimal institutional ownership at this time.

  • Read more about CONMED's insider trading history.
Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CNMD Stock News Headlines

CONMED (NYSE:CNMD) Price Target Raised to $46.00
CONMED (NYSE:CNMD) Earns Neutral Rating from Piper Sandler
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
CONMED Corp (CNMD) Q2 2026 Earnings
Conmed: Q2 Earnings Snapshot
See More Headlines

CNMD Stock Analysis - Frequently Asked Questions

CONMED's stock was trading at $40.56 at the beginning of the year. Since then, CNMD shares have increased by 20.8% and is now trading at $48.9940.

CONMED Corporation (NYSE:CNMD) posted its earnings results on Wednesday, July, 29th. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.11 by $0.27. The firm's revenue for the quarter was up .3% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of CONMED include BlackRock Inc. (16.10%), Bank of New York Mellon Corp (0.97%), Wedge Capital Management L L P NC (0.37%) and Deutsche Bank AG (0.11%). Insiders that own company stock include Charles Farkas, Pat Beyer, Martha Goldberg Aronson, Barbara J Schwarzentraub, Stanley W Peters III, Todd W Garner and Richard Glaze.
View institutional ownership trends
.

Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CONMED investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
7/29/2026
Today
8/09/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:CNMD
CIK
816956
Employees
3,900
Year Founded
1970

Price Target and Rating

High Price Target
$46.00
Low Price Target
$36.00
Potential Upside/Downside
-15.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.63
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.85
Trailing P/E Ratio
26.48
Forward P/E Ratio
10.79
P/E Growth
2.24
Net Income
$47.06 million
Net Margins
4.12%
Pretax Margin
6.07%
Return on Equity
14.31%
Return on Assets
6.33%

Debt

Debt-to-Equity Ratio
0.63
Current Ratio
1.48
Quick Ratio
0.69

Sales & Book Value

Annual Sales
$1.37 billion
Price / Sales
1.07
Cash Flow
$7.18 per share
Price / Cash Flow
6.82
Book Value
$33.36 per share
Price / Book
1.47

Miscellaneous

Outstanding Shares
29,950,000
Free Float
29,867,000
Market Cap
$1.47 billion
Optionable
Optionable
Beta
0.88

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NYSE:CNMD) was last updated on 8/9/2026 by MarketBeat.com Staff.
From Our Partners